Scott M K, Jacoby H I, Mills J E, Bonfilio A C, Rasmussen C R
J Med Chem. 1983 Apr;26(4):535-8. doi: 10.1021/jm00358a014.
4-(Diphenylmethyl)-1-piperidinemethanimine (1) is a potent oral gastric antisecretory agent in rats but contains a strong anticholinergic component. Since a nonanticholinergic gastric antisecretory drug would be useful in the treatment of peptic ulcer disease, a program was initiated by us to find such an agent based on 1. Compound 1 contains structural elements common to the anticholinergics atropine and homatropine. Studies on the structure-activity relationships of these compounds and their derivatives have revealed certain modifications that diminish or abolish anticholinergic activity. The application of these modifications to the design of analogues of 1 afforded an antisecretory compound, 4-(diphenylmethyl)-1-[(octylimino)methyl]piperidine (3h, fenoctimine), which exhibited no anticholinergic activity. Fenoctimine is undergoing clinical trial as a gastric antisecretory drug.
4-(二苯甲基)-1-哌啶甲亚胺(1)是一种对大鼠有效的口服胃泌素分泌抑制剂,但含有较强的抗胆碱能成分。由于非抗胆碱能胃泌素分泌抑制剂对消化性溃疡疾病的治疗有益,我们启动了一个项目,基于化合物1寻找这样一种药物。化合物1含有抗胆碱能药物阿托品和后马托品共有的结构元素。对这些化合物及其衍生物的构效关系研究揭示了某些能减少或消除抗胆碱能活性的修饰。将这些修饰应用于化合物1类似物的设计中,得到了一种胃泌素分泌抑制化合物,4-(二苯甲基)-1-[(辛基亚氨基)甲基]哌啶(3h,非诺替明),它没有抗胆碱能活性。非诺替明作为一种胃泌素分泌抑制药物正在进行临床试验。